Pfizer Inc. (NYSE: PFE) got their estimated earnings for Q2 2021 on 5th May, Wednesday by investment researchers from SVB Leerink. G. Porges now predicts the company to post a $1.06 EPS for the second quarter, which is an increase from the previous $0.80 estimate. SVB Leerink issued a rating of “Market Perform” with a target price of $43.
Detailed Stock Commentary Of PFE
Several brokerages have issued their reports on PFE stock recently. Morgan Stanley reduced their target price to $38 from $40 while setting a rating of “equal weight” on 29th January, Friday. TheStreet increased their rating for the stock to “b-” from “c+” on 3rd May, Monday. Mizuho decreased their rating to “neutral” from “buy” while setting a target price of $42 on Thursday. DZ Bank reissued a rating of “buy” and a target price of $41 on 3rd February, Wednesday. Finally, the Royal Bank of Canada issued a rating of “sector perform” while setting a price target of $42 on 7th April, Wednesday.
On Monday, the opening value of PFE shares stood at $39.58. The market capitalization value of the company currently stands at $20.76B with a 0.70 beta. The moving average of the stock over 50 days presently stands at $37.36 while for 200 days it is $36.82. The highest and lowest value of the stock in the past 12 months is $43.08 and $31.61 respectively. The latest results of its earnings were published on 4th May, Tuesday. A $0.93 EPS was reported overshooting the $0.78 general estimate.
Jennifer B. Damico, the SVP, sold off 2500 PFE shares at a $40.82 average price per share on 5th May, Wednesday. Merrion Investment Management Co LLC, Orion Capital Management LLC, Penbrook Management LLC, Alpha DNA Investment Management LLC, and Kinloch Capital LLC all boosted their share of PFE stocks.